公开(公告)号：US20220193010A1

公开(公告)日：2022-06-23

申请号：US17538749

申请日：2021-11-30

Applicant: INSIGNIS THERAPEUTICS, INC.

Inventor： Mingbao ZHANG

IPC: A61K31/137 ,  A61P37/00 ,  A61P11/00 ,  A61P31/00 ,  A61P11/06 ,  A61P37/08 ,  A61P31/04 ,  A61P11/16 ,  A61P35/00 ,  A61K9/00 ,  A61K47/38 ,  A61K47/42

Abstract: The disclosure provides a method for systemic delivery of a therapeutically effective amount of epinephrine to a subject comprising orally administering dipivefrin or a dipivefrin salt to the subject. The disclosure also includes a method of treatment of a disease amenable to treatment by in vivo delivery of systemic epinephrine comprising administering dipivefrin or a dipivefrin salt to a subject in need of in vivo delivery of systemic epinephrine. The disease can be a respiratory disorder, anaphylaxis, cancer, or a microbial infection. The disclosure also includes dipivefrin or dipivefrin HCl orally dissolving tablets.

公开(公告)号：US11365206B2

公开(公告)日：2022-06-21

申请号：US16795720

申请日：2020-02-20

Applicant: Newave Pharmaceutical Inc.

Inventor： Yi Chen ,  Yan Lou

IPC: A61P35/04 ,  A61P35/00 ,  A61P35/02 ,  A61P37/00 ,  C07D498/14 ,  C07D513/14 ,  A61K45/06 ,  A61K31/542 ,  A61K31/5383

Abstract: The disclosure includes compounds of Formula (A): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, and Q4, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neurodegenerative disease with these compounds.

公开(公告)号：US20220175835A1

公开(公告)日：2022-06-09

申请号：US17546469

申请日：2021-12-09

Applicant: CREATIVE MEDICAL TECHNOLOGIES, INC.

Inventor： Thomas Ichim ,  Amit Patel

IPC: A61K35/17 ,  A61K35/15 ,  C12N5/0784 ,  A61P37/00

Abstract: Disclosed are means, methods and compositions of matter useful for inhibiting, in an antigen-specific manner, immunity towards an autoantigen or alloantigen. In one embodiment of the invention, regenerative cells are cultured ex vivo together with immune cells from a mammal suffering from an autoimmune condition. Autoantigens or alloantigens are added in the culture of regenerative cells and cells from an autoimmune disease suffering individual in a manner so that said regenerative cells can endow onto said immune cells of said patient suffering from autoimmunity a state of antigen specific infectious tolerance. In one embodiment, said infectious tolerance involves T regulatory cells inducing conversion of dendritic cells to tolerogeneic dendritic cells, and furthermore in other embodiments administration of tolerogenic dendritic cells induces T regulatory cells.

公开(公告)号：US11351252B2

公开(公告)日：2022-06-07

申请号：US16453598

申请日：2019-06-26

Applicant: SNIPR Technologies Limited

Inventor： Jasper Clube

IPC: A61K39/00 ,  A61K39/395 ,  A61K35/15 ,  A61K35/17 ,  A61K31/7105 ,  A61P37/00 ,  A61P35/00

Abstract: The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.

公开(公告)号：US20220169742A1

公开(公告)日：2022-06-02

申请号：US17670223

申请日：2022-02-11

Applicant: Bristol-Myers Squibb Company

Inventor： Aaron YAMNIUK ,  Mary STRUTHERS ,  Stanley R. KRYSTEK, Jr. ,  Akbar NAYEEM ,  Ginger RAKESTRAW

IPC: C07K16/28 ,  A61K47/68 ,  A61K39/395 ,  C07K16/46 ,  A61P37/00

Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.

公开(公告)号：US11345747B2

公开(公告)日：2022-05-31

申请号：US16700471

申请日：2019-12-02

Applicant: LANKENAU INSTITUTE FOR MEDICAL RESEARCH

Inventor： Thomas Sunil ,  James Mullin ,  George C. Prendergast

IPC: A61K39/395 ,  A61K45/06 ,  A61K39/00 ,  C07K16/18 ,  A61P37/00

Abstract: Compositions and methods for the treatment of a disease or disorder are disclosed. Specifically, methods for inhibiting, treating, and/or preventing inflammatory disease in patients in need thereof are provided. The methods comprise the administration of at least one antibody or antibody fragment immunologically specific for bridging integrator I (Bin 1), particularly the Myc binding domain.

公开(公告)号：US11339149B2

公开(公告)日：2022-05-24

申请号：US16996507

申请日：2020-08-18

Applicant: Incyte Corporation

Inventor： Liangxing Wu ,  Jingwei Li ,  Wenqing Yao ,  Chao Qi ,  Ding-Quan Qian ,  Fenglei Zhang

IPC: A61K31/4375 ,  C07D413/14 ,  C07D471/04 ,  A61P37/02 ,  C07D498/04 ,  C07D513/04 ,  C07D487/04 ,  C07D413/06 ,  C07D413/12 ,  A61P37/00

Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

公开(公告)号：US20220152114A1

公开(公告)日：2022-05-19

申请号：US17665037

申请日：2022-02-04

Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

Inventor： Eric LAGASSE

IPC: A61K35/26 ,  A61P37/00

Abstract: The present disclosure provides methods and kits for preserving or restoring thymic functions of a subject in need thereof. The methods and kits disclosed herein include delivering an autologous thymic tissue into at least one lymph node of the subject.

公开(公告)号：US20220144962A1

公开(公告)日：2022-05-12

申请号：US17579468

申请日：2022-01-19

Applicant: Bristol-Myers Squibb Company

Inventor： Aaron YAMNIUK ,  Mary STRUTHERS ,  Stanley R. KRYSTEK, JR. ,  Akbar NAYEEM ,  Ginger RAKESTRAW

IPC: C07K16/28 ,  A61K47/68 ,  A61K39/395 ,  C07K16/46 ,  A61P37/00

Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.

公开(公告)号：US20220143140A1

公开(公告)日：2022-05-12

申请号：US17434247

申请日：2020-02-26

Applicant: Equillium, Inc. ,  University of Houston System

Inventor： Stephen Connelly ,  Krishna Polu ,  Chandra Mohan

IPC: A61K38/17 ,  G01N33/68 ,  A61P37/00 ,  A61K31/573 ,  A61K31/675 ,  A61K31/5377

Abstract: The present disclosure provides methods of treating inflammatory or autoimmune diseases (e.g., lupus nephritis) using CD6-ALCAM pathway inhibitors such as EQ001 and to methods and diagnostic tests for identifying subjects likely to respond to such inhibitors. In particular, the present disclosure provides diagnostic and therapeutic uses related to elevated levels of soluble ALCAM and/or CD6 protein and protein fragments in urine and other biological samples that are indicative of sensitivity to inhibitors of the CD6-ALCAM pathway (e.g., EQ001).